%0 Journal Article
%A Gambacorta, Maria Antonietta
%A Chiloiro, Giuditta
%A Masciocchi, Carlotta
%A Mariani, Silvia
%A Romano, Angela
%A Gonnelli, Alessandra
%A Gerard, Jean-Pierre
%A Ngan, Samuel
%A Rödel, Claus
%A Bujko, Krzysztof
%A Glynne-Jones, Robert
%A van Soest, Johan
%A Dekker, Andre
%A Damiani, Andrea
%A Valentini, Vincenzo
%T pCR and 2-Year Disease-Free Survival: A Combination of the Two Endpoints as a New Classification for Locally Advanced Rectal Cancer Patients-An Updated Pooled Analysis of Eleven International Randomized Trials.
%J Cancers
%V 15
%N 12
%@ 2072-6694
%C Basel
%I MDPI
%M DKFZ-2023-01295
%P 3209
%D 2023
%X LARC is managed by multimodal treatments whose intensity can be highly modulated. In this context, we need surrogate endpoints to help predict long-term outcomes and better personalize treatments. A previous study identified 2yDFS as a stronger predictor of OS than pCR in LARC patients undergoing neoadjuvant RT. The aim of this pooled analysis was to assess the role of pCR and 2yDFS as surrogate endpoints for OS in a larger cohort. The pooled and subgroup analyses were performed on large rectal cancer randomized trial cohorts who received long-course RT. Our analysis focused on the evaluation of OS in relation to the pCR and 2-year disease status. A total of 4600 patients were analyzed. Four groups were identified according to intermediate outcomes: 12
%K disease-free survival (Other)
%K intermediate endpoints (Other)
%K new risk-based classification (Other)
%K pathological complete response (Other)
%K personalized treatment (Other)
%K rectal cancer (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37370819
%R 10.3390/cancers15123209
%U https://inrepo02.dkfz.de/record/277133